LakeShore Biopharma Transitions to OTC Market
Ticker: LSBWF · Form: 6-K · Filed: Sep 22, 2025 · CIK: 1946399
| Field | Detail |
|---|---|
| Company | Lakeshore Biopharma CO., LTD. (LSBWF) |
| Form Type | 6-K |
| Filed Date | Sep 22, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: transition, market-move, company-name-change
TL;DR
LakeShore Biopharma is moving to the OTC market effective 9/22/25.
AI Summary
LakeShore Biopharma Co., Ltd. announced its transition to the OTC market, effective September 22, 2025. This move follows the company's previous name changes from YishengBio Co., Ltd. to YS Biopharma Co., Ltd. in March 2023. The company is headquartered in Beijing, PRC.
Why It Matters
This transition could impact the liquidity and accessibility of LakeShore Biopharma's shares for investors.
Risk Assessment
Risk Level: medium — Transitioning to an OTC market can sometimes indicate financial or regulatory challenges, potentially increasing risk for investors.
Key Players & Entities
- LakeShore Biopharma Co., Ltd. (company) — Registrant
- YS Biopharma Co., Ltd. (company) — Former company name
- YishengBio Co., Ltd. (company) — Former company name
- September 22, 2025 (date) — Effective date of OTC transition
- 001-41598 (other) — Commission file number
FAQ
What is the effective date of LakeShore Biopharma's transition to the OTC market?
The transition to the OTC market is effective September 22, 2025.
What were the previous names of LakeShore Biopharma Co., Ltd.?
The company was formerly known as YS Biopharma Co., Ltd. and YishengBio Co., Ltd.
When did the company change its name from YishengBio Co., Ltd.?
The name change from YishengBio Co., Ltd. occurred on September 12, 2022.
When did the company change its name from YS Biopharma Co., Ltd.?
The name change from YS Biopharma Co., Ltd. occurred on March 10, 2023.
What is the primary business address of LakeShore Biopharma?
The primary business address is Building No. 2, 38 Yongda Road, Daxing Biomedical Industry Park, Daxing District, Beijing, PRC.
Filing Stats: 174 words · 1 min read · ~1 pages · Grade level 11.5 · Accepted 2025-09-22 08:10:17
Filing Documents
- ea0258205-6k_lakeshore.htm (6-K) — 10KB
- ea025820501ex99-1_lakeshore.htm (EX-99.1) — 9KB
- 0001213900-25-089823.txt ( ) — 21KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Commission file number: 001-41598 LAKESHORE BIOPHARMA CO., LTD (Exact name of registrant as specified in its charter) Building No. 2, 38 Yongda Road Daxing Biomedical Industry Park Daxing District, Beijing, PRC Tel: 010-89202086 (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F EXHIBITS Exhibit No. Description 99.1 Press Release - LakeShore Biopharma Announces Transition to OTC Market Following Nasdaq Delisting 1 Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. LakeShore Biopharma Co., Ltd By: /s/ Rachel Yu Name: Rachel Yu Title: Director and Chief Financial Officer Date: September 22, 2025 2